AAJ0 Stock Overview
Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$17.20 |
| 52 Week Low | US$2.02 |
| Beta | 1.26 |
| 1 Month Change | -23.13% |
| 3 Month Change | -22.56% |
| 1 Year Change | -79.80% |
| 3 Year Change | -39.05% |
| 5 Year Change | n/a |
| Change since IPO | -84.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAJ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 4.1% |
| 1Y | -79.8% | -10.0% | 17.2% |
Return vs Industry: AAJ0 underperformed the German Biotechs industry which returned -10% over the past year.
Return vs Market: AAJ0 underperformed the German Market which returned 17.2% over the past year.
Price Volatility
| AAJ0 volatility | |
|---|---|
| AAJ0 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: AAJ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AAJ0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 118 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Perspective Therapeutics, Inc. Fundamentals Summary
| AAJ0 fundamental statistics | |
|---|---|
| Market cap | €151.94m |
| Earnings (TTM) | -€52.96m |
| Revenue (TTM) | €1.43m |
102.4x
P/S Ratio-2.8x
P/E RatioIs AAJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAJ0 income statement (TTM) | |
|---|---|
| Revenue | US$1.56m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.56m |
| Other Expenses | US$59.27m |
| Earnings | -US$57.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 26, 2025
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,706.62% |
| Debt/Equity Ratio | 0.5% |
How did AAJ0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 03:35 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perspective Therapeutics, Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Alec Stranahan | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |